Enzyme News and Research

RSS

Curemark reaches targeted enrollment in CM-AT Phase III clinical trials for autism

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that the company has completed its targeted enrollment of Phase III clinical trials for CM-AT, its autism treatment.

21 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Synageva BioPharma closes $25 million private equity financing

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, announced today the closing of a $25 million private equity financing.

21 Mar 2011

Researcher to present study on validation of salivary-biomarkers for pSS patients

Saturday, March 19, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher A.N.M. Nazmul-Hossaini will hold an oral presentation on a study titled "Validation of Salivary-Biomarkers for Sj-gren's Syndrome Detection in US Population."

19 Mar 2011

Scientists devise new strategy to prevent spread of drug-resistant bacteria

A team of scientists from the University of Oxford, U.K. have taken lessons from Adam Smith and Charles Darwin to devise a new strategy that could one day slow, possibly even prevent, the spread of drug-resistant bacteria. In a new research report published in the March 2011 issue of GENETICS, the scientists show that bacterial gene mutations that lead to drug resistance come at a biological cost not borne by nonresistant strains.

19 Mar 2011

Scientists discover enzyme family that plays a crucial role in regulating cell motility

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered that members of an enzyme family found in humans and throughout the plant and animal kingdoms play a crucial role in regulating cell motility. Their findings suggest an entirely new strategy for treating conditions ranging from diabetic ulcers to metastatic cancer.

19 Mar 2011

Springer editor receives ERC Advanced Grants for biosilicate research

The European Research Council has awarded one of this year's ERC Advanced Grants to Springer editor Dr. Werner M-ller, thus supporting his well-established research in the field of biosilicates with prize money of 2.2 million euros.

19 Mar 2011

Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma

Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20, the company's novel enzyme-based treatment for malignant mesothelioma.

19 Mar 2011

Modified mRNA raises hope for safe and effective cancer drugs

Modern gene therapies raise hopes of combating many diseases until now considered terminal. Nowadays, however, the methods are expensive and carry a risk of severe complications.

18 Mar 2011

New drug can aid in smoking reduction therapy

Researchers working in a research project within the Academy of Finland's Research Programme on Substance Use and Addictions have been developing a targeted drug that could aid in smoking reduction therapy. The new drug slows down the metabolism of nicotine, which would help smokers to cut down their smoking.

18 Mar 2011

GenSpera strengthens intellectual property for second prostate cancer drug

GenSpera, Inc. announced that its patent application, entitled "Activation of Peptide Prodrugs by HK2," has been issued by the United States Patent and Trademark Office (USPTO) as US Patent 7,906,477.

17 Mar 2011

pIMAGO nanopolymer can test cancer drug efficacy against biochemical processes

A Purdue University scientist's nanopolymer would make it easier and cheaper for drug developers to test the effectiveness of a widely used class of cancer inhibitors.

17 Mar 2011

New study on how epoxyeicosatrienoic acids protect kidneys

Researchers at Georgia Health Sciences University are studying whether inhibiting an enzyme that reduces levels of a protective metabolite could halt the progression of diabetic nephropathy, or kidney disease resulting from diabetes.

16 Mar 2011

Elite controllers' T cells resist HIV-1 infection by selective upregulation of protein p21

In the years since the AIDS epidemic began, it has become clear that there is substantial variation in the way that individuals respond to HIV infection. Although most progress quickly from initial infection to immunodeficiency, a small subset survive for long periods without developing symptoms.

16 Mar 2011

BRAF gene defect leads to pilocytic astrocytoma in children

Pilocytic astrocytoma, the most common brain tumor in children, is usually slow-growing and benign. However, surgeons often cannot completely remove the diffusely growing tumor.

16 Mar 2011

Apeiron in antitumor substances deal with Cleveland Clinic

APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents.

15 Mar 2011

Researchers discover new key component in lung cancer spread

Researchers discovered a new, key component in the spread of lung cancer as well as a likely way to block it with drugs now in clinical trial. The study was published today (Monday, March 14) in the Journal of Clinical Investigation.

15 Mar 2011

Scientists identify unique function of Twist1 in tumor metastasis

In the early stages of human embryogenesis, a transcription factor called Twist1 plays a key regulatory role in how the embryo assumes form and function. Much later in life, however, researchers at the University of California, San Diego School of Medicine, say Twist1 can re-emerge, taking a darker and more deadly turn.

15 Mar 2011

Elevated p21 expression may block key steps in viral life cycle

Elevated levels of p21, a protein best known as a cancer fighter, may be involved in the ability of a few individuals to control HIV infection with their immune system alone.

15 Mar 2011

Scientists show how E. coli strain causes infection in individuals

Scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, have shown how the O157:H7 strain of Escherichia coli causes infection and thrives by manipulating the host immune response.

15 Mar 2011